Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131

Michael A. Vogelbaum, Chen Hu, David M. Peereboom, David R. Macdonald, Caterina Giannini, John H. Suh, Robert Brian Jenkins, Nadia N Laack, David G. Brachman, Dennis C. Shrieve, Luis Souhami, Minesh P. Mehta

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent temozolomide was administered to patients with less than a complete radiographic response. Forty eligible patients were entered and 32 completed protocol treatment. With a median follow-up time of 8.7 years (range 1.1–10.1), median progression-free survival (PFS) is 5.8 years (95 % CI 2.0, NR) and median overall survival (OS) has not been reached (5.9, NR). 1p/19q data are available in 37 cases; 23 tumors had codeletion while 14 tumors had no loss or loss of only 1p or 19q (non-codeleted). In codeleted patients, 9 patients have progressed and 4 have died; neither median PFS nor OS have been reached and two patients who received only pre-RT temozolomide and no RT have remained progression-free for over 7 years. 3-year PFS and 6-year OS are 78 % (95 % CI 61–95 %) and 83 % (95 % CI 67–98 %), respectively. Codeleted patients show a trend towards improved 6-year survival when compared to the codeleted procarbazine/CCNU/vincristrine (PCV) and RT cohort in RTOG 9402 (67 %, 95 % CI 55–79 %). For non-codeleted patients, median PFS and OS are 1.3 and 5.8 years, respectively. These updated results suggest that the regimen of dose intense, pre-RT temozolomide followed by concurrent RT/temozolomide has significant activity, particularly in patients with 1p/19q codeleted AOs and MAOs.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalJournal of Neuro-Oncology
Volume124
Issue number3
DOIs
StatePublished - Jun 19 2015

Fingerprint

temozolomide
Oligodendroglioma
Astrocytoma
Radiotherapy
Disease-Free Survival
Survival
Lomustine
Procarbazine
Monoamine Oxidase
Clinical Protocols

Keywords

  • 1p/19q loss of heterozygosity
  • MGMT
  • Oligodendroglioma
  • RTOG
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas : long term results of RTOG BR0131. / Vogelbaum, Michael A.; Hu, Chen; Peereboom, David M.; Macdonald, David R.; Giannini, Caterina; Suh, John H.; Jenkins, Robert Brian; Laack, Nadia N; Brachman, David G.; Shrieve, Dennis C.; Souhami, Luis; Mehta, Minesh P.

In: Journal of Neuro-Oncology, Vol. 124, No. 3, 19.06.2015, p. 413-420.

Research output: Contribution to journalArticle

Vogelbaum, Michael A. ; Hu, Chen ; Peereboom, David M. ; Macdonald, David R. ; Giannini, Caterina ; Suh, John H. ; Jenkins, Robert Brian ; Laack, Nadia N ; Brachman, David G. ; Shrieve, Dennis C. ; Souhami, Luis ; Mehta, Minesh P. / Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas : long term results of RTOG BR0131. In: Journal of Neuro-Oncology. 2015 ; Vol. 124, No. 3. pp. 413-420.
@article{2c0da53fa5d34935995116d470e32dbf,
title = "Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131",
abstract = "We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent temozolomide was administered to patients with less than a complete radiographic response. Forty eligible patients were entered and 32 completed protocol treatment. With a median follow-up time of 8.7 years (range 1.1–10.1), median progression-free survival (PFS) is 5.8 years (95 {\%} CI 2.0, NR) and median overall survival (OS) has not been reached (5.9, NR). 1p/19q data are available in 37 cases; 23 tumors had codeletion while 14 tumors had no loss or loss of only 1p or 19q (non-codeleted). In codeleted patients, 9 patients have progressed and 4 have died; neither median PFS nor OS have been reached and two patients who received only pre-RT temozolomide and no RT have remained progression-free for over 7 years. 3-year PFS and 6-year OS are 78 {\%} (95 {\%} CI 61–95 {\%}) and 83 {\%} (95 {\%} CI 67–98 {\%}), respectively. Codeleted patients show a trend towards improved 6-year survival when compared to the codeleted procarbazine/CCNU/vincristrine (PCV) and RT cohort in RTOG 9402 (67 {\%}, 95 {\%} CI 55–79 {\%}). For non-codeleted patients, median PFS and OS are 1.3 and 5.8 years, respectively. These updated results suggest that the regimen of dose intense, pre-RT temozolomide followed by concurrent RT/temozolomide has significant activity, particularly in patients with 1p/19q codeleted AOs and MAOs.",
keywords = "1p/19q loss of heterozygosity, MGMT, Oligodendroglioma, RTOG, Temozolomide",
author = "Vogelbaum, {Michael A.} and Chen Hu and Peereboom, {David M.} and Macdonald, {David R.} and Caterina Giannini and Suh, {John H.} and Jenkins, {Robert Brian} and Laack, {Nadia N} and Brachman, {David G.} and Shrieve, {Dennis C.} and Luis Souhami and Mehta, {Minesh P.}",
year = "2015",
month = "6",
day = "19",
doi = "10.1007/s11060-015-1845-7",
language = "English (US)",
volume = "124",
pages = "413--420",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas

T2 - long term results of RTOG BR0131

AU - Vogelbaum, Michael A.

AU - Hu, Chen

AU - Peereboom, David M.

AU - Macdonald, David R.

AU - Giannini, Caterina

AU - Suh, John H.

AU - Jenkins, Robert Brian

AU - Laack, Nadia N

AU - Brachman, David G.

AU - Shrieve, Dennis C.

AU - Souhami, Luis

AU - Mehta, Minesh P.

PY - 2015/6/19

Y1 - 2015/6/19

N2 - We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent temozolomide was administered to patients with less than a complete radiographic response. Forty eligible patients were entered and 32 completed protocol treatment. With a median follow-up time of 8.7 years (range 1.1–10.1), median progression-free survival (PFS) is 5.8 years (95 % CI 2.0, NR) and median overall survival (OS) has not been reached (5.9, NR). 1p/19q data are available in 37 cases; 23 tumors had codeletion while 14 tumors had no loss or loss of only 1p or 19q (non-codeleted). In codeleted patients, 9 patients have progressed and 4 have died; neither median PFS nor OS have been reached and two patients who received only pre-RT temozolomide and no RT have remained progression-free for over 7 years. 3-year PFS and 6-year OS are 78 % (95 % CI 61–95 %) and 83 % (95 % CI 67–98 %), respectively. Codeleted patients show a trend towards improved 6-year survival when compared to the codeleted procarbazine/CCNU/vincristrine (PCV) and RT cohort in RTOG 9402 (67 %, 95 % CI 55–79 %). For non-codeleted patients, median PFS and OS are 1.3 and 5.8 years, respectively. These updated results suggest that the regimen of dose intense, pre-RT temozolomide followed by concurrent RT/temozolomide has significant activity, particularly in patients with 1p/19q codeleted AOs and MAOs.

AB - We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent temozolomide was administered to patients with less than a complete radiographic response. Forty eligible patients were entered and 32 completed protocol treatment. With a median follow-up time of 8.7 years (range 1.1–10.1), median progression-free survival (PFS) is 5.8 years (95 % CI 2.0, NR) and median overall survival (OS) has not been reached (5.9, NR). 1p/19q data are available in 37 cases; 23 tumors had codeletion while 14 tumors had no loss or loss of only 1p or 19q (non-codeleted). In codeleted patients, 9 patients have progressed and 4 have died; neither median PFS nor OS have been reached and two patients who received only pre-RT temozolomide and no RT have remained progression-free for over 7 years. 3-year PFS and 6-year OS are 78 % (95 % CI 61–95 %) and 83 % (95 % CI 67–98 %), respectively. Codeleted patients show a trend towards improved 6-year survival when compared to the codeleted procarbazine/CCNU/vincristrine (PCV) and RT cohort in RTOG 9402 (67 %, 95 % CI 55–79 %). For non-codeleted patients, median PFS and OS are 1.3 and 5.8 years, respectively. These updated results suggest that the regimen of dose intense, pre-RT temozolomide followed by concurrent RT/temozolomide has significant activity, particularly in patients with 1p/19q codeleted AOs and MAOs.

KW - 1p/19q loss of heterozygosity

KW - MGMT

KW - Oligodendroglioma

KW - RTOG

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84942502112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942502112&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1845-7

DO - 10.1007/s11060-015-1845-7

M3 - Article

C2 - 26088460

AN - SCOPUS:84942502112

VL - 124

SP - 413

EP - 420

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -